Rating Change
Barclays reiterated its Overweight rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) on November 05, 2026.
reiterateNASDAQ:RARE
Barclays Reiterates Overweight Rating on Ultragenyx Pharmaceutical Inc. (RARE)
Barclays reiterated its Overweight rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) on November 05, 2026.
At publication ·
What changed
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) · reiterate
- Firm
- Barclays
- Rating
- Overweight to Overweight
- Price at event
- $15.57
- Market capitalization
- $3.5B
At a glance
Key takeaways
- Barclays maintained an Overweight rating on Ultragenyx Pharmaceutical (RARE) on November 5, 2026, while the stock trades at $15.57 with a $3.5B market cap.
Market Context
Ultragenyx Pharmaceutical Inc. operates in the Healthcare sector. The stock currently trades at $15.57 with a market capitalization of $3.5B. The stock has declined 48.7% over the past 52 weeks.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Ultragenyx Pharmaceutical Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Ultragenyx Pharmaceutical Inc.
Among the 10 most recent ratings: 4 Buy, 6 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Nov 05, 2026 | Barclays | Overweight | N/A |
| Nov 04, 2026 | Canaccord Genuity | Buy | N/A |
| Nov 04, 2026 | Wells Fargo | Equal-Weight | N/A |
| Nov 04, 2026 | Goldman Sachs | Neutral | N/A |
| Nov 04, 2026 | Morgan Stanley | Equal-Weight | N/A |
Related Tools: Analyst Ratings Dashboard | View RARE Stock Page
Frequently Asked Questions
What does the Overweight rating mean for RARE?
A rating of Overweight from Barclays reflects the analyst's outlook on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RARE forecast page.